ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ANKTIVA® (nogapendekin alfa inbakicept-pmln) for the treatment of lymphopenia. Supplemental Biologics License Application (sBLA): In Q1, ImmunityBio completed the submission to the FDA of an sBLA for the use of ANKTIVA plus BCG in BCG-unrespon.
- 04/15/2025
|
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of Immu.
- 04/08/2025
|
Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities
- SAN DIEGO , April 7, 2025 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA IN RE IMMUNITYBIO, INC. SECURITIES LITIGATION No.
- 04/07/2025
|
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations, U.S. and global regulatory advances of its clinical-stage products, with fireside chats hosted by Dr. Patrick Soon-Shiong and key opinion leaders involved in the company's research programs. The discus.
- 04/07/2025
|
ImmunityBio: Taking Care Of Business
- ImmunityBio, Inc.'s recent progress on Anktiva and rBCG, including FDA submissions and collaborations, positions the company for significant revenue growth despite current financial challenges. The severe BCG shortage impacts Anktiva's growth, but ImmunityBio's rBCG efforts could fill the supply gap and potentially redefine NMIBC treatment. Despite strong commercial momentum, ImmunityBio's financial health remains a concern, with a quarterly cash burn rate of $104.4M and a cash runway of less than four months.
- 04/03/2025
|
ImmunityBio to Host Investor Day
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials. “ImmunityBio commenced 2025 with.
- 03/26/2025
|
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
- ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC.
- 03/07/2025
|
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates
- ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago.
- 03/03/2025
|
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the fourth-quarter and full year ended December 31, 2024. With the issuance of the permanent J-code in January 2025, ImmunityBio has seen increased sales momentum supporting a trend of increases month-over-month as well as quarter-over-quarter,.
- 03/03/2025
|
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on August 29, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company.
- 02/27/2025
|
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ANKTIVA® and CAR-NK (PD-L1 t-haNK) for the reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer. The complete blood count (CBC) is a standard assay wi.
- 02/27/2025
|
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing authorization application for ANKTIVA. The MHRA will now begin assessing the marketing authorization application (MAA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive.
- 02/13/2025
|
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, Ltd.), a global oncology company, to conduct a confirmatory randomized Phase 3 clinical trial (ResQ201A-NSCLC), combining BeiGene's tislelizumab, a PD-1 checkpoint inhibitor (CPI), and ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept-pmln). The Phase 3 ResQ201A-NSCLC study (NCT06745908) aims to co.
- 01/29/2025
|
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun assessing the marketing authorization application (MAA) for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tu.
- 01/27/2025
|
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
- ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities.
- 01/17/2025
|
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK
- ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.
- 01/17/2025
|
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
- On Wednesday, ImmunityBio, Inc. IBRX released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC).
- 01/16/2025
|
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC). NMIBC BCG Unresponsive Papillary Disease: ImmunityBio is preparing to submit a supplemental Biologics License Application (sBLA) in 2025.
- 01/15/2025
|
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to both the European Union (EU) European Medicines Agency (EMA) and the United King.
- 01/15/2025
|
ImmunityBio: Forging A New Plan After Recent $100 Million Offering
- ImmunityBio's recent $100M public offering was necessary to support ANKTIVA's commercialization and pipeline programs, despite the dilution and lower offering price of $3 per share. The company's cash burn rate and financial health remain concerns, but ANKTIVA's impressive performance and future milestones could drive substantial growth and extend the cash runway. IBRX's financial risks persist, and multiple offerings may be needed before profitability, but the potential for explosive revenue growth by 2029 supports a bullish outlook.
- 12/16/2024
|
ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success
- ImmunityBio's Anktiva shows promise with potential peak revenues of ~$900m annually, but faces significant competition and financial challenges, including a poorly timed $100m fundraising effort. Despite recent setbacks, including a Q3 net loss of $80m and a cash position of $130m, I maintain a "Buy" rating, anticipating positive 2025 catalysts. Anktiva's efficacy in NMIBC and potential in NSCLC + other cancers are potentially compelling, but the company needs substantial funding to complete ongoing and planned clinical studies.
- 12/13/2024
|
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
- CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares were sold by ImmunityBio. Before deducting the underwriting discount and offering expenses payable by ImmunityBio, ImmunityBio expects to receive gross proceeds of approximately $100.0 million, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about December 12, 2024 subject to satisfaction of customary closing conditions.
- 12/12/2024
|
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of.
- 12/11/2024
|
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, ImmunityBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.
- 12/10/2024
|
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
- FREMONT, Calif. , Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration agreement aimed at automating and streamlining the data fulfillment process for clinical trials.
- 11/21/2024
|
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 184.4% in ImmunityBio (IBRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 11/19/2024
|
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
- SAN FRANCISCO , Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2023 to secure regulatory approval for its flagship product Anktiva, designed to treat bladder cancer. Current shareholders are encouraged to contact the firm.
- 11/19/2024
|
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates
- ImmunityBio (IBRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.
- 11/12/2024
|
ImmunityBio Reports Third-Quarter 2024 Financial Results
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). ImmunityBio has secured coverage for over 200 million medical.
- 11/12/2024
|
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on June 30, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company.
- 10/30/2024
|
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025
- ImmunityBio's stock traded higher by 37% after dosing the first patient in its phase 1 QUILT 106 study for CD19+/CD20+ NHL, with data expected in 2025. The company's ANKTIVA therapy, combined with Keytruda or Opdivo, showed promising results in phase 2b for NSCLC, leading to upcoming phase 3 studies. The company has around $130.1 million in cash, bolstered by a $100 million infusion, enough to fund operations for at least the next 12 months.
- 10/28/2024
|
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock?
- ImmunityBio (IBRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 10/28/2024
|
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
- EF Hutton has initiated coverage on ImmunityBio Inc. IBRX, a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectious diseases.
- 10/23/2024
|
ImmunityBio to Participate in the Jefferies London Healthcare Conference
- CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Conference, which is taking place November 19-21 at the Waldorf Hilton London. Details of the presentation can be found below. Jefferies London Healthcare Conference Date: Tuesday, November 19, 2024 Time: 2:30 PM GT Format: Fireside chat with ImmunityBio company executives A replay of the recorded firesid.
- 10/21/2024
|
ImmunityBio: Moving The Needle
- ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospects. Recent positive clinical data for ANKTIVA in NSCLC and endometrial cancer trials highlight its potential beyond bladder cancer, boosting its long-term growth outlook. Despite significant advancements, risks include regulatory hurdles, commercialization challenges, high cash burn, and reliance on founder Dr. Patrick Soon-Shiong for funding.
- 10/07/2024
|
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
- Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial challenges, relying heavily on loans from founder Dr. Soon-Shiong, leading to high indebtedness. The company has a market cap of $2.43bn but limited cash runway, raising concerns about its financial stability and lack of recent earnings calls.
- 09/21/2024
|
Top 3 Health Care Stocks That Are Set To Fly This Quarter
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 08/16/2024
|
ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'
- ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows promising market access initiatives, but financial concerns remain due to high R&D costs. Analysts project peak revenues of ~$900m by 2028 for Anktiva, although at present, Immunity's pricing of the drug is a little hard to understand.
- 08/14/2024
|
ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates
- ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago.
- 08/12/2024
|
Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm
- NEW YORK , July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
- 07/25/2024
|
7 Biotech Stocks to Keep on Your Clinical Radar
- Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.
- 07/23/2024
|
3 Top Cancer Treatment Stocks to Buy Now
- Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.
- 07/17/2024
|
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
- ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
- 06/26/2024
|
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the initial treatment of multiple patients in the United States to receive therapy with ANKTIVA® (nogapendekin alfa inbakicept-pmln), ImmunityBio's recently approved immunotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. ANKTIVA was approved by the U.S. Food and Drug Administration (FDA) on April 22, 2024 for the treatment of patients with B.
- 06/20/2024
|
3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions
- A short-squeeze stocks to buy are something investors need to watch out for. If investors believe that a stock's price will fall within a certain time frame, they will enter a short position.
- 06/20/2024
|
These 5 stocks are potential short-squeeze candidates
- In recent weeks, extreme volatility in specific stocks has resurged following the return of popular trader Keith Gill, also known as Roaring Kitty, to social media. After a nearly four-year hiatus, Gill disclosed a sizable stake in GameStop (NYSE: GME), reigniting interest in the stock.
- 06/14/2024
|
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Off.
- 06/07/2024
|
ImmunityBio: Anktiva's Launch Demands A Reassessment
- ImmunityBio's flagship product, Anktiva, has been launched in the market for the treatment of bladder cancer, with strong clinical data supporting its efficacy. The company is well-prepared for the launch, with a strong sales force, established distribution channels, and sufficient inventory. Analyst projections suggest significant growth for ImmunityBio, with the potential for Anktiva to become a blockbuster drug and drive the company's revenue in the coming years.
- 06/06/2024
|
Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company's recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cancer research. Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific at ImmunityBio, discussed the breakin.
- 05/17/2024
|
The 3 Best Bargain Stocks to Buy in May 2024
- There are several types of bargain stocks available to buy in the stock market. There are, of course, traditional bargain stocks with very low valuations and an average growth rate.
- 05/09/2024
|
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for “fill finish” (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg ANKTIVA (nogapendekin alfa inbakicept-pmln). Coupled with the recent announcement of a partnership with the Serum Institute of India (SII) for BCG availability, this provides the Company with a significant initial supply of ANKTIVA for com.
- 05/07/2024
|
Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells
- You'll get no argument from me that GameStop (NYSE: GME ) is one of the best meme stocks to sell. However, the video game retailer has been around a long time, suggesting it's not the worst of the meme stocks to sell.
- 05/06/2024
|
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
- CULVER CITY, Calif.--(BUSINESS WIRE)--The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. (NASDAQ: IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors at the American Urological Association.
- 04/30/2024
|
What's going on with the ImmunityBio (IBRX) stock price?
- ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva, its cancer drug. It has risen for two straight days and is now sitting at its highest level since September 2021.
- 04/29/2024
|
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab) and standard-of-care chemotherapy to be discussed during the upcoming conference call. The results continue to reinforce ImmunityBio's belief in the unique mechanism of action of ANKTIVA (N-803, o.
- 04/25/2024
|
Here's why ImmunityBio (IBRX) stock price surged and what next
- ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After dropping by over 6% in the regular session on Monday, it rebounded by over 20% in the extended session.
- 04/23/2024
|
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. “The FDA's approval of ANKTIVA marks our launch of a next-generation immun.
- 04/22/2024
|
U.S. FDA approves ImmunityBio's bladder cancer therapy
- The U.S. Food and Drug Administration approved ImmunityBio's combination therapy to treat a type of bladder cancer, the regulator said on Monday, allowing the company's first product to market.
- 04/22/2024
|
2 Stocks Under $20: Immunitybio and Lemonade
- Depending on who you ask, a recession is either right around the corner, or the stock market is ready to rattle off a seismic bull run.
- 03/20/2024
|
5 Stocks with Unusually Large Short Interest
- With the broader market reaching new all-time highs, primarily driven by the tech sector and specifically semiconductor stocks fueled by the hype surrounding AI, the spotlight is once again beginning to shine on high short-interest stocks.
- 03/08/2024
|
Showcasing Seeking Alpha's February 2024 New Analysts
- A record 39 new analysts joined us in February 2024, bringing fresh perspectives and ideas to the community.
- 03/06/2024
|
ImmunityBio: Buy Low Now Vs. Buy High Later
- Pre-PDUFA positioning is a good opportunity to buy ImmunityBio stock at a low price. Multiple catalysts could drive the stock price higher over the next 24 months. ImmunityBio has the potential to become a big pharma company rather than being sold.
- 02/11/2024
|
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
- Two factors –lower interest rates and the low valuation of many biotech stocks — are likely to result in many biotech companies being acquired in 2024. Lower interest rates will result in many drug maker stocks being acquired because cheaper borrowing costs will make it cheaper for firms to borrow the money that they need to finance deals.
- 01/02/2024
|
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023. The additional capital provides significant financial resources for the Company to accelerate its commercialization efforts in anticipation of a potential regulat.
- 01/02/2024
|
Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock Now
- After losing some value lately, a hammer chart pattern has been formed for ImmunityBio (IBRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 12/04/2023
|
ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross
- ImmunityBio, Inc. (IBRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IBRX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
- 11/27/2023
|
First Data for ImmunityBio's Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced new data showing that the company's Memory Cytokine-Enriched Natural Killer cells (M-ceNK) may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors. Findings from the study titled “Characterization of the anti-tumor activity of memory cytokine enriched NK cells (M-ceNK) against tumors with neuroendocrine feature.
- 11/07/2023
|
3 Biotech Moonshots to Bet on the Future of Health
- Biotech stocks are incredibly risky but can provide investors with huge returns since insurers in the U.S. will pay tremendous amounts for successful treatments. In the last few months in particular, the potential risks of biotech stocks have increased only a bit while their possible returns have increased tremendously.
- 11/06/2023
|
Should You Still Buy the Nasdaq's Best-Performing October Stocks?
- Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that its bladder cancer drug will now be better understood by the FDA.
- 11/03/2023
|
ImmunityBio: The CRL Makes It Riskier Than Ever
- ImmunityBio, Inc.'s drug Anktiva received a Complete Response Letter, or CRL, from the FDA, delaying its approval for the treatment of NMIBC. The CRL was related to deficiencies in the FDA's inspection of the company's third-party contract manufacturing organizations. ImmunityBio's financial situation, including a large debt owed to its founder, raises concerns about its ability to succeed and prioritize shareholder interests.
- 10/24/2023
|
Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch ASAP
- Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greater volatility. When penny stocks become heavily shorted, meaning a high percentage of the shares are held by investors betting the price will decline, it can set up a volatile “short squeeze.
- 09/15/2023
|
Why Shares of ImmunityBio Jumped This Week
- The clinical-stage biotech's lead therapy is in trials to treat bladder cancer. The sale of company stock helped raise $470 million.
- 09/15/2023
|
3 Very Oversold Biotech Stocks to Buy Right Now
- After I spent many years following Wall Street, there are a few characteristics about the “big money” that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks that have a 60%-80% chance of climbing a great deal in the long term but a 10%-15% chance of plunging in the short-to-medium term.
- 08/29/2023
|
Looking for a Bargain? 3 Biotech Stocks to Buy That Are Down 20%-60% in 2023
- American drug makers can generate gigantic profits, pushing their stock prices to great heights. The pharmaceutical sector is lucrative in general around the globe, while the space is very profitable in America in particular.
- 08/01/2023
|
Why Shares of ImmunityBio Were Up on Wednesday
- ImmunityBio is a clinical-stage biotech company. The company's lead therapy candidate is Anktiva.
- 07/19/2023
|
ImmunityBio Can Recover From BLA Dip
- The FDA rejected the Anktiva marketing application last month. Since the troubles lie with an outside organization, the company has no control over the resolution. The drug is good, so resubmission, approval, and partnership are all still in play.
- 06/20/2023
|
7 High-Risk, High-Reward Stocks to Buy in June
- There are some similarities between gambling and buying high-risk, high-reward stocks. In both scenarios, you could make a great deal of money or you could lose all of it.
- 06/12/2023
|
4 Penny Stocks To Buy In June According To Insiders
- Penny stocks are often characterized by their high volatility. Their low price means that even small price changes can equate to significant percentage gains or losses.
- 06/06/2023
|
ImmunityBio: Amidst Difficulty Is Your Opportunity
- Being an extremely volatile stock, ImmunityBio, Inc. is not for all investors. Nevertheless, there are tremendous opportunities in ImmunityBio stock for investors who can stomach higher risks and substantial volatility.
- 05/17/2023
|
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
- FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.
- 05/12/2023
|
ImmunityBio: Anktiva Rejection Heightens Financial Urgency
- ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Despite manufacturing deficiencies, the lack of additional FDA requests for preclinical studies or Phase 3 clinical trials hints at eventual approval.
- 05/12/2023
|
Why Is ImmunityBio (IBRX) Stock Down 54% Today?
- ImmunityBio (NASDAQ: IBRX ) stock is falling on Thursday after the company got a complete response letter from the FDA. That letter has to do with the company's Biologics License Application (BLA) for Anktiva in combination with Bacillus CalmetteGuérin.
- 05/11/2023
|
2 Pharma Stocks in Focus on FDA Buzz
- Immunitybio Inc (NASDAQ:IBRX) stock is crumbling today, down 52.1% at $2.98 at last glance, and earlier as low as $2.45, after the U.S. Food and Drug Administration (FDA) declined to approve its bladder cancer therapy.
- 05/11/2023
|
ImmunityBio in dramatic selloff as FDA puts bladder cancer treatment on hold
- ImmunityBio Inc shares were sinking fast on Thursday morning after receiving notice from the US Food and Drug Administration that its Biologics License Application was put on hold for its bladder cancer treatment Anktiva. The FDA determined that the BLA cannot be approved in its current form due to deficiencies found during a pre-license inspection of the company's third-party contract manufacturer.
- 05/11/2023
|
ImmunityBio stock loses more than half its value after disclosing FDA can't approve the BLA for its cancer treatment in its present form
- Shares of ImmunityBio Inc. IBRX plummeted 53.7% toward a record one-day selloff in premarket trading Thursday, after the immunotherapy company disclosed it received a “complete response letter” from the U.S. Food and Drug Administration, but puts the company's Biologics License Application (BLA) for its bladder cancer treatment Anktiva (N-803) on hold. The FDA determined that it can't approve the BLA in its present form as a pre-license inspection of the company's third-party contract manufacturer found deficiencies.
- 05/11/2023
|
The 7 Most Undervalued Growth Stocks for Your May Buy List
- With short sellers viciously attacking many popular stocks and Wall Street worrying too much about the macroeconomic outlook, there are a multitude of undervalued growth stocks for investors to buy now. Plus, three recent factors have increased my optimism about growth stocks.
- 05/08/2023
|
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?
- ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 05/08/2023
|
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
- In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.
- 04/16/2023
|
Top Penny Stocks To Buy Now? 10 To Watch Under $5
- 10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/13/2023
|
ImmunityBio: FDA Approval Potential In May Of 2023
- ImmunityBio, Inc. has a PDUFA date of May 23, 2023, for potential FDA approval of N-803 + BCG for the treatment of patients with BCG-unresponsive CIS non-muscle invasive bladder cancer. It is said that the global bladder cancer market could reach $11.5 billion by 2032.
- 04/12/2023
|
7 Top Penny Stocks Under $5; Time To Buy Now?
- Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now?
- 03/29/2023
|
ImmunityBio: Huge Slump On Small Raise Before Approval Raises Questions
- ImmunityBio, Inc. has a May 23 PDUFA for Anktiva with superb data in NMIBC. A recent small $50mn raise broke the stock's back.
- 03/27/2023
|
ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances
- ImmunityBio, Inc. presented strong data from its lead asset in multiple indications. Lead indication has a May 23 PDUFA.
- 01/06/2023
|
ImmunityBio: PDUFA Pending
- ImmunityBio operates an effective development program for infectious disease, and more interestingly, oncology therapies. Its duly accepted BLA will be in the spotlight as its PDUFA date rolls around.
- 10/17/2022
|
7 Unknown Biotech Stocks That Could Rocket in 2023
- Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
- 09/23/2022
|
ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain
- Shares of ImmunityBio have lost nearly 90% of their value since merger with NantKwest last year. Ties to biotech billionaire Patrick Soon-Shiong are a net positive, especially in light of his success selling prior company Abraxis to Pfizer for $2.9 billion.
- 08/07/2022
|
7 Best Pharmaceutical Stocks to Buy Now
- These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.
- 07/20/2022
|
ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission
- ImmunityBio has finally submitted the Anktiva (N-803) and BCG combination BLA in NMIBC ahead of the final clinical results presentation at ASCO. The company is still moving forward with multiple cancer and infectious disease programs with Anktiva. An FDA approval would improve the outlook for these programs.
- 06/02/2022
|
7 Cheap Biotech Stocks to Buy Now
- These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on InvestorPlace.
- 05/19/2022
|
Bonds Are Screaming “Recession.” That's Great News For One Top Sector.
- The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.
- 03/29/2022
|
ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter
- BLA filing of Anktiva + BCG in BCG-unresponsive cancer in Situ non-muscle invasive bladder cancer patients is expected Q1 of 2022.
- 03/15/2022
|
Immunitybio (IBRX) Stock: Why THe Price Went Up
- The stock price of Immunitybio Inc (NASDAQ: IBRX) increased by 4.64% in the most recent trading session. This is why it happened.
- 02/02/2022
|
ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial
- ImmunityBio Inc (NASDAQ: IBRX) has revealed early results from its Phase 2 metastatic pancreatic cancer trial (QUILT 88), showing that patients' overall survival rate doubled compared to the historical survival rate. Phase 2 evaluates the comparative efficacy and overall safety of standard-of-care chemotherapy versus low-dose chemotherapy combined with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in locally advanced or metastatic pancreatic cancer.
- 01/19/2022
|
ImmunityBio Stock (IBRX): Why The Price Surged Today
- The stock price of Immunitybio Inc (NASDAQ: IBRX) increased by 23.85% today. This is why it happened.
- 01/03/2022
|
Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture
- Amyris Inc (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX) have completed their previously announced joint venture agreement to accelerate the commercialization of a next-generation COVID-19 vaccine. Upon completion of human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as it is practically possible to deliver.
- 01/03/2022
|
ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat
- ImmunityBio is preparing to submit their BLA in NMIBC in the first quarter of 2022. The company is moving forward with several COVID-19 vaccine programs with different technologies.
- 12/27/2021
|
Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine
- Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19 vaccine. The parties have signed a binding term sheet, and a definitive agreement is in process and is expected to be executed within the next month.
- 11/08/2021
|
ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial
- ImmunityBio Inc (NASDAQ: IBRX) has announced that Papillary disease (Cohort B) of its Phase 2/3 study of intravesical BCG plus Anktiva met its primary endpoints with disease-free survival of 57% at 12 months. Non-muscle invasive bladder cancer (NMIBC) makes up 75%-85% of all bladder cancers in the U.S.; approximately 90% of NMIBC cases are papillary.
- 10/19/2021
|
ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price
- ImmunityBio's share price bearish trend continues since its merger despite Anktiva moving closer to a BLA submission in BCG-unresponsive non-muscle-invasive carcinoma in situ bladder cancer.
- 10/12/2021
|
ImmunityBio: Market Has Lost Contact Following Merger
- The ImmunityBio and NantKwest merger has created a clinical powerhouse in immunotherapy. The share price continues to show weakness since the merger with little reaction to positive news. It is possible the market has lost sight of IBRX, despite several programs moving closer to the finish line.
- 07/19/2021
|
ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors Patients
- ImmunityBio Inc (NASDAQ: IBRX) has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva (N-803) in locally advanced/metastatic solid tumors. Cryopreserved m-ceNK cells combined with Anktiva will be tested in this QUILT 3.076 Phase 1 study designed to evaluate the safety in subjects.
- 05/17/2021
|
ImmunityBio (IBRX) Stock: Over 10% Increase Explanation
- The stock price of ImmunityBio Inc (NASDAQ: IBRX) increased by over 10% during intraday trading. This is why it happened.
- 05/17/2021
|
7 of the Best Pharma Stocks to Buy Now
- As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on InvestorPlace.
- 05/11/2021
|
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
- Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
- 05/04/2021
|
ImmunityBio: Remaining Bullish As Global Vaccine Apparatus Continues To Misfire
- ImmunityBio and NantKwest have merged, creating a juggernaut pre-clinical and clinical pipeline. The share price has been weak since the merger, however I remain bullish at these prices. The company has an impressive COVID-19 vaccine candidate that could be best-in-class and possibly help end the pandemic.
- 04/16/2021
|
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
- ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.
- 04/09/2021
|
Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses
- ImmunityBio Inc (NASDAQ: IBRX) has reported initial data from the Phase 1 study evaluating its hAd5 COVID-19 vaccine candidate in healthy participants. Just 14-16 days after the single dose of the vaccine, the mean level of T cells generated in response to dual antigen hAd5 spike (S) + nucleocapsid (N) vaccine was ten times higher for N specific T cells.
- 04/08/2021
|
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
- CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today reported initial data indicating that a single subcutaneous injection of the company's COVID-19 vaccine candidate in healthy Phase 1 clinical study participants stimulates the generation of T cells that are reactive to the spike (S) and nucleocapsid (N) protein antigens delivered by the vaccine. Just 14-16 days after the single dose, the mean level of T cells generated in respon
- 04/08/2021
|
